TRIPS and the international public health controversies: Issues and challenges

Industrial and Corporate Change

Volumn 15, Issue 6, 2006, Pages 1033-1062

  Coriat, Benjamin ^a   Orsi, Fabienne ^b   d'Almeida, Cristina ^b  

^a UMR CNRS 7115)   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEVELOPING WORLD; HEALTH POLICY; INTELLECTUAL PROPERTY RIGHTS; NORTH-SOUTH RELATIONS; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH; TRADE;

BRAZIL; SOUTH AMERICA;

EID: 33845689575     PISSN: 09606491     EISSN: 14643650     Source Type: Journal    
DOI: 10.1093/icc/dtl029     Document Type: Article

References (37)

1. Arrow, K. (1962), 'Economic welfare and allocation of resources for invention,' in R. Nelson (ed.), The Rate and Direction of Inventive Activity. Princeton University Press: Princeton.
2. Bayard, T. and K. Eliott (1994), Reciprocity and Retaliation in US Trade Policy. Institute for International Economics: Washington DC.
3. Bhagwati, J. (1991), The World Trading System at Risk. MIT Press.
4. Coriat, B. and F. Orsi (2002), 'Establishing a new regime of intellectual property rights in the United States. Origins, content and problems,' Research Policy, 32, 1491-1507.
5. Coriat, B., F. Orsi and O. Weinstein (2003), 'Science-based technological regimes and institutions: Does biotech reflect a new science based regime?' Industry and Innovation.
6. Coriat, B. and F. Orsi (2006), 'TRIPS, pharmaceutical patent and public health - The case for access to HIV Care,' in S. Libby (ed.), Global Regulation: Managing Crises After the Imperial Turn. Palagrave, MacMillan, New York.
7. Corréa, C. (1999), Intellectual Property Rights and the Use of Compulsory Licenses: Options for Developing Countries. South Centre: Geneva.
8. Corréa, C. M (2004), 'Bilateralism in intellectual property: defeating the WTO system for access to medicines,' Case Western Reserve Journal of International Law, 36(1), Winter 79-94.
9. Grangeiro, A., L. Teixeira, F. Bastos and P. Teixeira (2006), 'Sustainability of Brazilian policy for acess to antiretroviral drugs,' Revista de Saude Publica, 40(supl), 1-9.
10. Heller, M. and R. Eisenberg (1998), 'Can patent deter innovation? The anti-commons tragedy in biomedical research,' Science, 280, 698-701.
11. Luchini, S., B. Cisse, S. Durand and J.-P. Maotti (2003), 'Decrease in prices of antiretroviral drugs for developing countries: From political "philanthropy" to regulated markets?', in J. P. Moatti, B. Coriat, Y. Souteyrand et al. (eds) Economics of AIDS and Access to HIV Care in Developing Countries. Issues and Challenges. Editions de l' ANRS, Paris. pp. 169-211.
12. Mazzucato, M. and G. Dosi (2006), Knowledge Accumulation and Industry Evolution, The Case of Pharma-Biotech. Cambridge University Press: Cambridge.
13. Merrill, S., R. Levin and B. Myers (2004), A Patent System for the 21st Century. The National Academies Press: Washington DC, available at http://www.nap.edu.
14. Moatti, J. P., B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin and Y. A. Flori (eds) (2003), Economics of AIDS and Access to HIV Care in Developing Countries. Issues and Challenges. Editions de l' FANRS, Paris.
15. Nelson, R. (1959), 'The simple economics of basic scientific research,' Journal of Political Economy, 67(3), 297-306.
16. Nelson, R. (2006), 'The market economy and the scientific commons,' in B. Andersen (ed.), Intellectual Property Rights: Innovation, Governance and the Institutional Environment. Edward Elgar: London. pp. 17-45.
17. Orsenigo, G. Dosi and M. Mazzucato (2006), 'The dynamics of knowledge accumulation, regulation and appropraibility in the phrama-biotech sector,' in M. Mazzucato and G. Dosi (2006).
18. Orsi, F. and B. Coriat (2005), 'Are "strong patents" beneficial to innovative activities? The case of genetic testing for breast cancer,' Industrial and Corporate Change, 14(6), 1205-1221.
19. Orsi, F. and B. Coriat (2006), 'The new role and status of intellectual property rights in contemporary capitalism', Competition and Change, 1(2), 162-179.
20. Orsi, F., M. Camara and B. Coriat (2006), 'AIDS, TRIPS and "TRIPS plus." The case for developing and less developed countries,' in B. Andersen (ed.), Intellectual Property Rights: Innovation, Governance and the Institutional Environment, Edward Elgar pp. 70-106.
21. Orsi, F., L. Hasenclever, B. Fialho, P. Tigre and B. Coriat (2003), 'Intellectual property rights, anti-aids policy and generic drugs: lesson from the Brazilian public health program', in J. P. Moatti, B. Coriat and Y. Souteyrand (eds), Economics of AIDS and Access to HIV Care in Developing Countries. Issues and Challenges. ANRS editions; Paris, pp. 109-135.
22. Orsi, F., C. Sevilla and B. Coriat (2006), 'Upstream patents and public health: The case for genetic testing of breast cancer,' in M. Mazzucato and G. Dosi, (eds), (2006), pp. 327-345.
23. Pammoli, F., L. Magazzini and L. Orsenigi (2002) 'The intensity of competition after patent expiry in pharmaceuticals. A cross country analysis,' Revue d'Economie Industrielle, 99(2), 107-132. (Special Issue on 'Intellectual Property Rights' coordinated by Benjamin CORIAT).
24. Rai, A. (2001), 'Fostering cumulative innovation in the biopharmaceutical industry: The role of patents and antitrust,' Berkeley Technology Law Journal, 16, 813-853.
25. Rai A. and R. Eisenberg (2003), 'Bayh-Dole Reform and the progress of biomedicine,' Law and Contemporary Problems, 66, 289-313.
26. Reichman, L and C. Hasenzahl (2002), 'Non-voluntary licensing of patented inventions: Historical perspective, legal framework under TRIPS, and an overview of the practice in Canada and the United States of America,' UNCTAD/ICTSD Working Paper.
27. Reichman, J. and D. Lange (2000), 'Bargaining around the trips agreement: The case for ongoing public-private initiatives to facilitate worldwide intellectual property transactions,' Ducke Journal of Comparative & International Law, 9(11) 11-68.
28. Remiche, B. and R. Desterbecq (1996), 'Les brevets pharmaceutiques dans les Accords du GATT: L'enjeu?' Revue Internationale de Droit Economique, 1, 7-68.
29. Roffe, P. (2004), Bilateral Agreements and a TRIPS-Plus World: The Chile-USA Free Trade Agreement, TRIPS Issues paper 4, QUNO, Geneva, available at http://www.qiap.ca or http://www.geneva.quno.info.
30. Roffe P., G. Transey and D. Visas-Eugui (2006), Negotiating Health. Intellectual Property and Access to Medicines. Earthcan: London.
31. Scherer, F. M. (1993), 'Pricing, profits and technological progress in the pharmaceutical industry,' Journal of Economic Perspectives, 7(3), 97-115.
32. Scherer, F. M. and J. Watal (2001), 'Post-trips option for access to patented medicines in developing countries,' CMH Working Paper Series, NWG4: 1.
33. t'Hoen, E. (2003), 'TRIPS, pharmaceutical patents and access to essential medicines: Seattle, Doha and beyond,' in J. P. Moatti, B.Coriat, Y. Souteyrand et al. (eds), Economics of AIDS and Access to HIV Care in Developing Countries. Issues and Challenges. Editions de l' ANRS, Paris. pp. 39-67.
34. T'Hoen, E. (2005), European union committee on international trade - Hearings on TRIPS and access to medicines, Tuesday 18 January, Strassburg.
35. Van Puymbroeck, R. V. (2003), Exportation of drugs under compulsory licenses: The WTO decision on implementation of paragraph 6 of the Doha Declaration on the TRIPS agreement and public health, Working Paper.
36. World Health Organization (2004), Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach 2003, Revisited version, available at http://www.who.org.
37. Zhang, S. (1994), De l'OMPI an GATT - La protection internationale des droits de propriété intellectuelle, ITEC: Paris.